Abstract:

During the last 15 years, Straumann together with the leading clinicians worldwide have studied Roxolid SLActive implants under the most challenging conditions and treatment protocols to understand the performance limits and osseopromotion potential of Roxolid SLActive. 

As new insights emerge and new data becomes available, it is time to report how you can benefit from the high performance SLActive® surface to support your patients’ healing capabilities.

Speaker: Alex Ostashko

CV:

Alex Ostashko is globally responsible for managing the three key Straumann brands: Roxolid®, SLActive® and ImmediaXy. Before joining the Straumann product management team in 2012, Alex worked for Cardinal Health and Park Hill Capital in sales, marketing, and portfolio management roles. Alex Ostashko is a strategic marketing professional with 20 years’ track record of finding opportunities and capitalizing on them in different client situations, technology environments and problem domains.